| |
Angelini Pharma secures exclusive global license rights to future identified drug targets
Quiver receives undisclosed advance payment and is eligible for future milestone-dependent payments and royalties
Collaboration further expands Angelini Pharma’s focus on brain health, building on its deep therapeutic expertise and drug development experience |
| |
| |
| |
| 上一篇：Lenovo推出新一代AI驱动型ThinkEdge解决方案，释放数据潜力 |
| 下一篇：AOP Health关于罕见病：信息共享 |
| |
| |
| |
